Literature DB >> 33545021

Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research Program.

Annette T Hastie1, David T Mauger2, Loren C Denlinger3, Andrea Coverstone4, Mario Castro4, Serpil Erzurum5, Nizar Jarjour3, Bruce D Levy6, Deborah A Meyers7, Wendy C Moore1, Brenda R Phillips2, Sally E Wenzel8, John V Fahy9, Elliot Israel6, Eugene R Bleecker7.   

Abstract

Rationale: Some reports indicate longitudinal variability in sputum differential cell counts, whereas others describe stability. Highly variable sputum eosinophil percentages are associated with greater lung function loss than persistently elevated eosinophil percentages, but elevated neutrophils are linked to more severe asthma.
Objectives: To examine sputum granulocyte stability or variability longitudinally and associations with important clinical characteristics.
Methods: The SARP III (Severe Asthma Research Program III) cohort underwent comprehensive phenotype characterization at baseline and annually over 3 years. Adult subjects with acceptable sputum levels were assigned to one of three longitudinal sputum groups: eosinophils predominantly <2%, eosinophils predominantly ≥2%, or highly variable eosinophil percentages (>2 SDs determined from independent, repeated baseline eosinophil percentages). Subjects were similarly assigned to one of three longitudinal neutrophil groups with a 50% cut point.Measurements and Main
Results: The group with predominantly <2% sputum eosinophils had the highest lung function (prebronchodilator FEV1% predicted, P < 0.01; FEV1/FVC ratio, P < 0.001) at baseline and throughout 3 years compared with other eosinophil groups. Healthcare use did not differ, although the highly variable eosinophil group reported more asthma exacerbations at Year 3. Longitudinal neutrophil groups showed few differences. However, a combination of predominantly ≥2% eosinophil and ≥50% neutrophil groups resulted in the lowest prebronchodilator FEV1% predicted (P = 0.049) compared with the combination with predominantly <2% eosinophils and<50% neutrophils.Conclusions: Subjects with predominantly ≥2% sputum eosinophils in combination with predominantly ≥50% neutrophils showed greater loss of lung function, whereas those with highly variable sputum eosinophils had greater healthcare use.

Entities:  

Keywords:  eosinophils; exacerbations; healthcare use; longitudinal inflammation; neutrophils

Mesh:

Year:  2021        PMID: 33545021      PMCID: PMC8017570          DOI: 10.1164/rccm.202009-3713OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  29 in total

1.  Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples.

Authors:  Mohammed T Al-Samri; Andrea Benedetti; David Préfontaine; Ron Olivenstein; Catherine Lemière; Parameswaran Nair; James G Martin; Qutayba Hamid
Journal:  J Allergy Clin Immunol       Date:  2010-04-14       Impact factor: 10.793

2.  Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes.

Authors:  Annette T Hastie; Wendy C Moore; Deborah A Meyers; Penny L Vestal; Huashi Li; Stephen P Peters; Eugene R Bleecker
Journal:  J Allergy Clin Immunol       Date:  2010-04-15       Impact factor: 10.793

3.  Baseline sputum eosinophil + neutrophil subgroups' clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort.

Authors:  Annette T Hastie; David T Mauger; Loren C Denlinger; Andrea Coverstone; Mario Castro; Serpil Erzurum; Nijar Jarjour; Bruce D Levy; Deborah A Meyers; Wendy C Moore; Brenda Phillips; Sally E Wenzel; John V Fahy; Elliot Israel; Eugene R Bleecker
Journal:  J Allergy Clin Immunol       Date:  2020-02-05       Impact factor: 10.793

4.  Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids.

Authors:  Michael C Peters; Sheena Kerr; Eleanor M Dunican; Prescott G Woodruff; Merritt L Fajt; Bruce D Levy; Elliot Israel; Brenda R Phillips; David T Mauger; Suzy A Comhair; Serpil C Erzurum; Mats W Johansson; Nizar N Jarjour; Andrea M Coverstone; Mario Castro; Annette T Hastie; Eugene R Bleecker; Sally E Wenzel; John V Fahy
Journal:  J Allergy Clin Immunol       Date:  2018-03-07       Impact factor: 10.793

5.  Asthma Control and Sputum Eosinophils: A Longitudinal Study in Daily Practice.

Authors:  Sophie F Demarche; Florence N Schleich; Virginie A Paulus; Monique A Henket; Thierry J Van Hees; Renaud E Louis
Journal:  J Allergy Clin Immunol Pract       Date:  2017-04-25

6.  Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age.

Authors:  W Gerald Teague; Brenda R Phillips; John V Fahy; Sally E Wenzel; Anne M Fitzpatrick; Wendy C Moore; Annette T Hastie; Eugene R Bleecker; Deborah A Meyers; Stephen P Peters; Mario Castro; Andrea M Coverstone; Leonard B Bacharier; Ngoc P Ly; Michael C Peters; Loren C Denlinger; Sima Ramratnam; Ronald L Sorkness; Benjamin M Gaston; Serpil C Erzurum; Suzy A A Comhair; Ross E Myers; Joe Zein; Mark D DeBoer; Anne-Marie Irani; Elliot Israel; Bruce Levy; Juan Carlos Cardet; Wanda Phipatanakul; Jonathan M Gaffin; Fernando Holguin; Merritt L Fajt; Shean J Aujla; David T Mauger; Nizar N Jarjour
Journal:  J Allergy Clin Immunol Pract       Date:  2017-08-31

7.  Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma.

Authors:  M Kupczyk; B Dahlén; P J Sterk; E Nizankowska-Mogilnicka; A Papi; E H Bel; P Chanez; P H Howarth; S T Holgate; G Brusselle; N M Siafakas; M Gjomarkaj; S-E Dahlén
Journal:  Allergy       Date:  2014-07-08       Impact factor: 13.146

8.  Phenotyping of difficult asthma using longitudinal physiological and biomarker measurements reveals significant differences in stability between clusters.

Authors:  T Zaihra; C J Walsh; S Ahmed; C Fugère; Q A Hamid; R Olivenstein; J G Martin; A Benedetti
Journal:  BMC Pulm Med       Date:  2016-05-10       Impact factor: 3.317

9.  Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study.

Authors:  Matthew J Loza; Ratko Djukanovic; Kian Fan Chung; Daniel Horowitz; Keying Ma; Patrick Branigan; Elliot S Barnathan; Vedrana S Susulic; Philip E Silkoff; Peter J Sterk; Frédéric Baribaud
Journal:  Respir Res       Date:  2016-12-15

10.  Detailed analysis of sputum and systemic inflammation in asthma phenotypes: are paucigranulocytic asthmatics really non-inflammatory?

Authors:  Sophie Demarche; Florence Schleich; Monique Henket; Virginie Paulus; Thierry Van Hees; Renaud Louis
Journal:  BMC Pulm Med       Date:  2016-04-05       Impact factor: 3.317

View more
  9 in total

Review 1.  Sterols in asthma.

Authors:  Mireia Guerau-de-Arellano; Rodney D Britt
Journal:  Trends Immunol       Date:  2022-08-27       Impact factor: 19.709

Review 2.  Extracellular Traps: A Novel Therapeutic Target for Severe Asthma.

Authors:  Youngwoo Choi; Quoc Quang Luu; Hae-Sim Park
Journal:  J Asthma Allergy       Date:  2022-06-14

Review 3.  Specialized pro-resolving mediators in respiratory diseases.

Authors:  R Elaine Cagnina; Melody G Duvall; Julie Nijmeh; Bruce D Levy
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2022-03-01       Impact factor: 4.294

4.  Granulocytic Airway Inflammation and Clinical Asthma Outcomes.

Authors:  Renaud E Louis; Florence N Schleich
Journal:  Am J Respir Crit Care Med       Date:  2021-04-01       Impact factor: 21.405

5.  Serum Amyloid A1: A Biomarker for Neutrophilic Airway Inflammation in Adult Asthmatic Patients.

Authors:  Tra Cao Thi Bich; Quang Luu Quoc; Youngwoo Choi; Eun-Mi Yang; Hoang Kim Tu Trinh; Yoo Seob Shin; Hae-Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2022-01       Impact factor: 5.764

6.  Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts.

Authors:  Yuki Hoshino; Tomoyuki Soma; Yoshitaka Uchida; Yuki Shiko; Kazuyuki Nakagome; Makoto Nagata
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

7.  Validation and further insight into the International Severe Asthma Registry (ISAR) eosinophil gradient algorithm in the Wessex AsThma CoHort of difficult asthma (WATCH) using historical blood eosinophil counts and induced sputum.

Authors:  Clair Barber; Adnan Azim; Colin Newell; Aref Kyyaly; Hitasha Rupani; Hans Michael Haitchi; Peter Howarth; Ramesh Kurukulaaratchy
Journal:  Clin Exp Allergy       Date:  2022-02-21       Impact factor: 5.401

8.  Targeting ETosis by miR-155 inhibition mitigates mixed granulocytic asthmatic lung inflammation.

Authors:  Ji Young Kim; Patrick Stevens; Manjula Karpurapu; Hyunwook Lee; Joshua A Englert; Pearlly Yan; Tae Jin Lee; Navjot Pabla; Maciej Pietrzak; Gye Young Park; John W Christman; Sangwoon Chung
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786

Review 9.  Recent insights in the role of biomarkers in severe asthma management.

Authors:  Evangelia Fouka; Kalliopi Domvri; Foteini Gkakou; Maria Alevizaki; Paschalis Steiropoulos; Despoina Papakosta; Konstantinos Porpodis
Journal:  Front Med (Lausanne)       Date:  2022-09-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.